Amphotericin B
- Generic Name
- Amphotericin B
- Brand Names
- Abelcet, Ambisome, Amphotec, Fungizone
- Drug Type
- Small Molecule
- Chemical Formula
- C47H73NO17
- CAS Number
- 1397-89-3
- Unique Ingredient Identifier
- 7XU7A7DROE
- Background
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
- Indication
Used to treat potentially life threatening fungal infections.
- Associated Conditions
- Coccidioidomycosis, Fungal Infections, Histoplasmosis, Invasive Aspergillosis, Invasive Fungal Infections, Leishmaniasis, Meningitis, Cryptococcal, Meningitis, Fungal, Mucocutaneous Leishmaniasis, Mycotic endophthalmitis, Penicillium marneffei infection, Visceral Leishmaniasis, Candidal cystitis, Disseminated Cryptococcosis, Fungal osteoarticular infections, Ocular aspergillosis, Refractory aspergillosis, Severe Coccidioidomycosis, Severe Cryptococcosis, Severe Fungal infection caused by Basidiobolus spp., Severe Fungal infection caused by Conidiobolus spp., Severe Fungal infection caused by sporotrichosis spp., Severe Histoplasmosis, Severe Mucocutaneous leishmaniasis, Severe North American blastomycosis, Severe Systemic candidiasis
Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis
- Conditions
- HIV/AIDS-associated Talaromycosis
- Interventions
- First Posted Date
- 2025-04-13
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Shanghai Public Health Clinical Center
- Target Recruit Count
- 116
- Registration Number
- NCT06926569
Antifungal Drugs in Pulmonary Mucormycosis
- Conditions
- Pulmonary Mucormycosis
- Interventions
- Drug: Combination therapy group
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- Bin Cao
- Target Recruit Count
- 312
- Registration Number
- NCT06756191
Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection
- Conditions
- Neonatal InfectionInvasive Fungal Infections
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 56
- Registration Number
- NCT06413056
- Locations
- 🇪🇬
Ain Shams University Hospitals, Cairo, Abbassia, Egypt
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly
- Conditions
- Leishmaniasis; BrazilianLeishmaniasis, Mucocutaneous
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of Brasilia
- Target Recruit Count
- 100
- Registration Number
- NCT06040489
- Locations
- 🇧🇷
Hospital Universitario de Brasilia, Brasilia, DF, Brazil
Bioequivalence of Amphotericin B Liposome for Injection
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2023-09-28
- Target Recruit Count
- 32
- Registration Number
- NCT05913921
- Locations
- 🇨🇳
Haikou people's Hospital, Haikou, Hainan, China
Pharmacokinetics and Safety of AmBisome and DKF-5122
- Conditions
- Invasive Fungal InfectionsNeutropenic Fever
- Interventions
- First Posted Date
- 2023-03-01
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Dongkook Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05749380
- Locations
- 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho-gu, Korea, Republic of
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
- Conditions
- Primary Visceral Leishmaniasis
- Interventions
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Drugs for Neglected Diseases
- Target Recruit Count
- 105
- Registration Number
- NCT05593666
- Locations
- 🇮🇳
DrugsNeglectedD Investigational Site, Patna, India
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
- Conditions
- Cryptococcal Meningitis
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05541107
Amphotericin Versus Posaconazole for Pulmonary Mucormycosis
- Conditions
- Mucormycosis; Pulmonary (Etiology)
- Interventions
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Target Recruit Count
- 30
- Registration Number
- NCT05468372
- Locations
- 🇮🇳
Postgraduate Institute of Medical Education and Research, Chandigarh, India
Olorofim Aspergillus Infection Study
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- F2G Biotech GmbH
- Target Recruit Count
- 225
- Registration Number
- NCT05101187
- Locations
- 🇧🇪
Hôpital Erasme, Bruxelles, Belgium
🇫🇷Hospital Claude Huriez, Lille, Nord, France
🇪🇸Hospital Universitari i Politecnic La Fe, Valencia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.